OurCrowd portfolio company, MigVax Corp., an Israeli company developing a vaccine for COVID-19, has selected Eyal Desheh as chairman of its board of directors.
Desheh has previously served as an executive at Teva Pharmaceuticals, Check Point Software Technologies and currently is on the Board of Directors of Isracard Group. He has a B.A. in economics and an M.B.A. in finance, both from the Hebrew University of Jerusalem.
“I am very happy to join this global effort to defeat the COVID-19 pandemic which has devastated our world by creating a severe health and economic crisis,” Mr. Desheh said in a release. “An amazing and talented team of scientists in the north of Israel created a promising infrastructure for the development of vaccines for COVID-19 and its like. At MigVax we are working as hard and as fast as we can to make this a reality.”
David Zigdon, MigVax interim CEO, said he looks forward to working closely with Deshesh as he brings years of top-tier experience in pharmaceuticals, business and technology to the MigVax team.
“We are confident that he is the right person to help create the multinational business relationships for MigVax.”
Jerusalem-based OurCrowd is leading a $12 million investment in MigVax, an affiliate of the Migal Galillee Research Institute.
Earlier this month, OurCrowd announced the launch of a $100 million Pandemic Innovation Fund.
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!
